Literature
1. Pierre SC, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K. Inhibition of cyclooxygenases by dipyrone. British journal of pharmacology 2007; 151: 494-503.
2. Tatsuo MA, Carvalho WM, Silva CV, Miranda AE, Ferreira SH, Francischi JN. Analgesic and antiinflammatory effects of dipyrone in rat adjuvant arthritis model. Inflammation 1994; 18: 399-405.
3. Alves D, Duarte I. Involvement of ATP-sensitive K(+) channels in the peripheral antinociceptive effect induced by dipyrone. Eur J Pharmacol 2002; 444: 47-52.
4. Escobar W, Ramirez K, Avila C, Limongi R, Vanegas H, Vazquez E. Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats. European Journal of Pain 2012; 16: 676-89.
5. Ortiz MI, Castaneda-Hernandez G, Granados-Soto V. Possible involvement of potassium channels in peripheral antinociception induced by metamizol: lack of participation of ATP-sensitive K+ channels. Pharmacol Biochem Behav 2003; 74: 465-70.
6. Siebel JS, Beirith A, Calixto JB. Evidence for the involvement of metabotropic glutamatergic, neurokinin 1 receptor pathways and protein kinase C in the antinociceptive effect of dipyrone in mice. Brain Res 2004; 1003: 61-7.
7. Vasquez E, Vanegas H. The antinociceptive effect of PAG-microinjected dipyrone in rats is mediated by endogenous opioids of the rostral ventromedical medulla. Brain Res 2000; 854: 249-52.
8. Valenzuela F, García-Saisó S, Lemini C, Ramírez-Solares R, Vidrio H, Mendoza-Fernández V. Metamizol acts as an ATP sensitive potassium channel opener to inhibit the contracting response induced by angiotensin II but not to norepinephrine in rat thoracic aorta smooth muscle. Vascular Pharmacology 2005; 43: 120-27.
9. Gulmez SE, Gurdal H, Tulunay FC. Airway Smooth Muscle Relaxations Induced by Dipyrone. Pharmacology 2006; 78: 202-08.
10. Asmardi G, Jamali F. Pharmacokinetics of dipyrone in man; role of the administration route. Eur J Drug Metab Pharmacokinet 1985; 10: 121-5.
11. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995; 28: 216-34.
12. Volz M, Kellner HM. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 1980; 10 Suppl 2: 299S-308S.
13. Zylber-Katz E, Granit L, Levy M. Formation and excretion of dipyrone metabolites in man. Eur J Clin Pharmacol 1992; 42: 187-91.
14. Levy M, Flusser D, Zylber-Katz E, Granit L. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 1984; 27: 453-8.
15. Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism in liver disease. Clin Pharmacol Ther 1995; 58: 198-209.
16. Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995; 25: 417-27.
17. Bast A, Noordhoek J. Product inhibition during the hepatic microsomal N-demethylation of aminopyrine in the rat. Biochem Pharmacol 1981; 30: 19-24.
18. Imaoka S, Inoue K, Funae Y. Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Arch Biochem Biophys 1988; 265: 159-70.
19. Inoue K, Fujimori K, Mizokami K, Sunouchi M, Takanaka A, Omori Y. Simultaneous determination of aminopyrine hydroxylation and aminopyrine N-demethylation in liver microsomes by high-performance liquid chromatography. J Chromatogr 1983; 274: 201-8.
20. La Du BN, Gaudette L, Trousof N, Brodie BB. Enzymatic dealkylation of aminopyrine (pyramidon) and other alkylamines. J Biol Chem 1955; 214: 741-5.
21. Noda A, Goromaru T, Tsubone N, Matsuyama K, Iguchi S. In vivo formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. I. Chem Pharm Bull (Tokyo) 1976; 24: 1502-5.
22. Noda A, Tsubone N, Mihara M, Goromaru T, Iguchi S. Formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. II. Enzymatic demethylation and oxidation of aminopyrine and 4-monomethylaminoantipyrine. Chem Pharm Bull (Tokyo) 1976; 24: 3229-31.
23. Geisslinger G, Bocker R, Levy M. High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharm Res 1996; 13: 1272-5.
24. Bachmann F, Duthaler U, Rudin D, Krahenbuhl S, Haschke M. N-demethylation of N-methyl-4-aminoantipyrine, the main metabolite of metamizole. Eur J Pharm Sci 2018; 120: 172-80.
25. Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, Krahenbuhl S. Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. Clin Pharmacol Ther 2020.
26. Luethi D, Hoener MC, Krahenbuhl S, Liechti ME, Duthaler U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol 2019; 164: 129-38.
27. Bachmann F, Blaser L, Haschke M, Krahenbuhl S, Duthaler U. Development and validation of an LC-MS/MS method for the bioanalysis of the major metamizole metabolites in human plasma. Bioanalysis 2020; 12: 175-89.
28. FDA. U.S. Department of Health and Human Services, Food and Drug Andministration (FDA): Bioanalytical Method Validation, Guidance for Industry. In, 2018.
29. Agúndez JA, Carrillo JA, Martínez C, Benítez J. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine. Therapeutic drug monitoring 1995; 17: 1-5.
30. Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, Krahenbuhl S. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2. Clin Pharmacol Ther 2020: in press.
31. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
32. FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. In, 2020.
33. Krisai P, Rudin D, Grünig D, Scherer K, Pichler W, Terracciano L, Krähenbühl S. Acute Liver Failure in a Patient Treated With Metamizole. Front Pharmacol 2019; 10: 996.
34. Blanca-López N, Pérez-Sánchez N, Agúndez JA, García-Martin E, Torres MJ, Cornejo-García JA, Perkins JR, Miranda MA, Andreu I, Mayorga C, Canto G, Blanca M, Doña I. Allergic Reactions to Metamizole: Immediate and Delayed Responses. International archives of allergy and immunology 2016; 169: 223-30.
35. Cismaru AL, Rudin D, Ibañez L, Liakoni E, Bonadies N, Kreutz R, Carvajal A, Lucena MI, Martin J, Sancho Ponce E, Molokhia M, Eriksson N, Eu DACC, Krähenbühl S, Largiadèr CR, Haschke M, Hallberg P, Wadelius M, Amstutz U. Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes 2020; 11.
36. Rudin D, Lanzilotto A, Bachmann F, Housecroft CE, Constable EC, Drewe J, Haschke M, Krähenbühl S. Non-immunological toxicological mechanisms of metamizole-associated neutropenia in HL60 cells. Biochem Pharmacol 2019; 163: 345-56.
37. Rudin D, Roos NJ, Duthaler U, Krähenbühl S. Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes. Toxicology 2019; 426: 152254.